Health TrialsbyHealthPanel

Cognitive Training Intervention and Attitudes Towards Genetics

ConditionsCognitive ImpairmentHematologic NeoplasmsHematopoietic Cell Transplant
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age21+
SponsorUniversity of Alabama at Birmingham

About this trial

A pilot study to evaluate feasibility of enrollment of patients in an intervention to improve neurocognitive function in hematopoietic cell transplantation (HCT) survivors using the cognitive training Lumosity program. In addition, patients' interest in receiving information regarding genetic risk of cognitive impairment post-HCT will be measured.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

≥ 21 years old at time of allogeneic HCT performed at UAB

Outpatient and between 3 and 6 months post HCT

English speaking

Possess access to an internet-connected home computer

Disqualifiers

History of pre-existing neurological disorder or documented major psychiatric disorder; significant auditory, visual, or motor impairments

Participated in neuropsychological intervention within the past 6 months

History of color blindness

Trial design

Design model

Parallel

Treatments tested in this trial

  • Lumosity

    Behavioral

    Computer-based online cognitive training program using the Lumosity cognitive training program.

  • Lumosity (waitlist control)

    Behavioral

    Computer-based online cognitive training program using the Lumosity cognitive training program. The control group will receive the intervention after a waiting period of 12 weeks.

Treatment groups

60 Participants
are divided into 2 treatment groups
Group A: InterventionExperimental treatment 1 intervention
Group B: Wait List ControlActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Number of HCT patients completing the 2-arm wait-listed randomized trial of cognitive training intervention for a period of 3 months

Number of participants completing the 12 week intervention

Time frame
12 weeks
2

Change in cognitive function between intervention and wait list control arms from baseline to 12 weeks.

Change in cognitive function will be measured using cognitive test scores at baseline and 12 weeks

Time frame
Baseline to 12 weeks

Secondary outcomes

1

16-item survey to measure genetic factual knowledge at baseline

Genetic factual knowledge will be measured using a 16-item survey on knowledge about genes, chromosomes, cells, and diseases and how different characteristics are inherited from parents.

Time frame
Baseline
2

Effect size of associations of key predictors with genetic factual knowledge at baseline

Effect size of associations of sociodemographic characteristics such as age, gender, race/ethnicity, education and income levels with genetic factual knowledge of participants will be measured.

Time frame
Baseline
3

5 Likert scale survey questionnaire to measure importance of receiving genetic risk information

Patient ratings will be collected on a 5 Likert scale survey questionnaire to examine importance of receiving information on genetic risk of cognitive impairment post-HCT.

Time frame
baseline
4

5 Likert scale survey questionnaire to measure impact of receiving genetic risk information on intervention uptake

Patient ratings will be collected on a 5 Likert scale survey questionnaire to measure association of likelihood of genetic risk of cognitive impairment (low chance vs high chance) on intervention uptake.

Time frame
baseline

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Alabama at Birmingham

Lead sponsor

Source ClinicalTrials.gov
Apply now